Statement of Ownership (sc 13g)
May 05 2017 - 4:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
AZURRX BIOPHARMA, INC.
(Name of Issuer)
Common stock, par value $0.0001 per share
(Title of Class of Securities)
05502L105
(CUSIP Number)
October 11, 2016
(Date of Event which
Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
[_] Rule 13d-1(b)
[_] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a
reporting persons initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be filed for the purpose of Section 18 of the
Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities
of that section of the Act but shall be subject to all other provisions of the
Act (however, see the
Notes
).
SCHEDULE 13G
1
|
Names of Reporting Persons
|
|
|
|
Richard Melnick
|
|
|
2
|
Check the appropriate box if a member of a Group (see
instructions)
|
|
|
|
(a) [
]
|
|
(b) [
]
|
|
|
3
|
Sec Use Only
|
|
|
|
|
4
|
Citizenship or Place of Organization
|
|
|
|
United States
|
|
5
|
Sole Voting Power
|
|
|
|
|
|
833,000
|
Number of
|
|
|
Shares
|
6
|
Shared Voting Power
|
Beneficially
|
|
0
|
Owned by Each
|
|
|
Reporting Person
|
7
|
Sole Dispositive Power
|
With:
|
|
|
|
|
833,000
|
|
|
|
|
8
|
Shared Dispositive Power
|
|
|
|
|
|
0
|
9
|
Aggregate Amount Beneficially Owned by Each Reporting
Person
|
|
|
|
833,000
|
|
|
10
|
Check box if the aggregate amount in row (9) excludes
certain shares (See Instructions)
|
|
|
|
[ ]
|
|
|
11
|
Percent of class represented by amount in row
(9)
|
|
|
|
8.6
|
|
|
12
|
Type of Reporting Person (See Instructions)
|
|
|
|
IN
|
Page 2 of 5
Item 1.
(a)
|
Name of Issuer:
|
|
|
|
AZURRX BIOPHARMA, INC.
|
|
|
(b)
|
Address of Issuers Principal Executive
Offices:
|
|
|
|
760 Parkside Avenue, Downstate Biotechnology Incubator,
Suite 304, Brooklyn, New York 11226
|
Item 2.
(a)
|
Name of Person Filing:
|
|
|
|
Richard Melnick
|
|
|
(b)
|
Address of Principal Business Office or, if None,
Residence:
|
|
|
|
P.O. Box 296, Crested Butte, CO 81224
|
|
|
(c)
|
Citizenship:
|
|
|
|
United States
|
|
|
(d)
|
Title and Class of Securities:
|
|
|
|
Common stock, par value $0.0001 per share
|
|
|
(e)
|
CUSIP No.:
|
|
|
|
05502L105
|
Item 3.
|
If this statement is filed
pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the
person filing is a:
|
|
(a)
|
[_]
|
Broker or dealer registered under Section 15 of
the Act;
|
|
|
|
|
|
(b)
|
[_]
|
Bank as defined in Section 3(a)(6) of the Act;
|
|
|
|
|
|
(c)
|
[_]
|
Insurance company as defined in Section
3(a)(19) of the Act;
|
|
|
|
|
|
(d)
|
[_]
|
Investment company registered under Section 8
of the Investment Company Act of 1940;
|
|
|
|
|
|
(e)
|
[_]
|
An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
|
|
|
|
|
|
(f)
|
[_]
|
An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
(g)
|
[_]
|
A parent holding company or control person in
accordance with Rule 13d-1(b)(1)(ii)(G);
|
|
|
|
|
|
(h)
|
[_]
|
A savings associations as defined in Section
3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
Page 3 of 5
|
(i)
|
[_]
|
A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment Company Act of
1940;
|
|
|
|
|
|
(j)
|
[_]
|
A non-U.S. institution in accordance with Rule
240.13d-1(b)(1)(ii)(J);
|
|
|
|
|
|
(k)
|
[_]
|
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If
filing as a non-U.S. institution in accordance with Rule
240.13d-1(b)(1)(ii)(J), please specify the type of institution:
______
|
Item 4. Ownership
(a)
|
Amount Beneficially Owned:
833,000
|
|
|
(b)
|
Percent of Class:
8.6
|
|
|
(c)
|
Number of shares as to which such person
has:
|
|
(i)
|
Sole power to vote or to direct the vote:
833,000
|
|
|
|
|
(ii)
|
Shared power to vote or to direct the vote:
0
|
|
|
|
|
(iii)
|
Sole power to dispose or to direct the disposition of:
833,000
|
|
|
|
|
(iv)
|
Shared power to dispose or to direct the disposition
of:
0
|
Item
5.
|
Ownership of Five Percent or
Less of a Class.
|
|
|
|
Not applicable.
|
|
|
Item
6.
|
Ownership of more than Five
Percent on Behalf of Another Person.
|
|
|
|
Not applicable.
|
|
|
Item
7.
|
Identification and
classification of the subsidiary which acquired the security being
reported on
by the parent holding company or control person.
|
|
|
|
Not applicable.
|
|
|
Item
8.
|
Identification and
classification of members of the group.
|
|
|
|
Not applicable.
|
|
|
Item
9.
|
Notice of Dissolution of
Group.
|
|
|
|
Not applicable.
|
|
|
Item
10.
|
Certifications.
|
|
|
|
Not applicable.
|
Page 4 of 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: May 5, 2017
/s/ Richard Melnick
Name/Title:
Richard Melnick
The original statement shall be signed by each person on whose
behalf the statement is filed or his authorized representative. If the statement
is signed on behalf of a person by his authorized representative (other than an
executive officer or general partner of this filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
Attention: Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001).
Page 5 of 5
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Apr 2023 to Apr 2024